1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,000 | 7,250 | 22.03. | |
| 7,100 | 7,150 | 20.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | LEADS BIOLABS-B (09887): DATE OF BOARD MEETING | - | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 09.03. | Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer | 301 | PR Newswire | NANJING, China, March 9, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026... ► Artikel lesen | |
| 06.03. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX AND INCLUSION IN THE STOCK LIST OF STOCK CONNECT ... | - | HKEx | ||
| 06.03. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN PHASE II TRIAL OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) ... | 1 | HKEx | ||
| 10.02. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) DOSED FIRST PATIENT IN PHASE IB/II TRIAL FOR ... | 2 | HKEx | ||
| 02.02. | XFRA NEW INSTRUMENTS AVAILABLE ON 02.02.2026 | 483 | Xetra Newsboard | The following instruments on XETRA do have their first trading 02.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.02.2026
Aktien
1 CA00249P1053 AXA S.A. CDR
2 ARP125991090... ► Artikel lesen | |
| 28.01. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-034 (GPRC5D/CD3 BISPECIFIC T-CELL ENGAGER, TCE) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA | 2 | HKEx | ||
| 22.01. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT ORPHAN DRUG DESIGNATION (ODD) OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) BY THE EUROPEAN ... | - | HKEx | ||
| 16.01. | Global News: Global Development Accelerates: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Granted Fast Track Designation by FDA | 552 | Newsfile | Nanjing, China--(Newsfile Corp. - January 15, 2026) - Nanjing Leads Biolabs Co., Ltd. (HKE: 9887) ("Leads Biolabs" or the "Company") today announced that Opamtistomig (LBL-024), its core investigational... ► Artikel lesen | |
| 14.01. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT- LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA | 2 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 3 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 23.12.25 | Leads Biolabs and Dianthus dose first subject in LBL-047 trial | 2 | Investing.com | ||
| 23.12.25 | Dianthus Therapeutics, Inc.: Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) | 271 | GlobeNewswire (Europe) | LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress... ► Artikel lesen | |
| 23.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN PHASE IB/II TRIAL FOR PLATINUM-RESISTANT OVARIAN CANCER | 2 | HKEx | ||
| 23.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 DOSED FIRST SUBJECT IN PHASE I TRIAL | 1 | HKEx | ||
| 17.12.25 | LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 17.12.25 | LEADS BIOLABS-B (09887): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 17, 2025 | - | HKEx | ||
| 15.12.25 | LEADS BIOLABS-B (09887): INSIDE INFORMATION - PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION PROGRAM BY THE COMPANY | 1 | HKEx |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,68 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| IMMUNOVANT | 22,980 | -2,69 % | Bernstein initiates Immunovant stock coverage with neutral rating | ||
| KYMERA THERAPEUTICS | 77,91 | -2,06 % | Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 | ||
| NURIX THERAPEUTICS | 14,430 | -3,25 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 60,92 | -5,18 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| QIAGEN | 34,805 | -1,28 % | Qiagen unter Druck, Zalando auf Erholungskurs: DAX-Ausblick | Der DAX befindet sich weiter auf Talfahrt. In der abgelaufenen Woche büßte das größte deutsche Börsenbarometer rund 144 Punkte ein und schloss -0,61% niedriger mit 23.447 Punkten. Die höchsten Verluste... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,210 | +0,54 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,170 | -0,85 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,000 | +1,13 % | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20... ► Artikel lesen | |
| IMMIX BIOPHARMA | 9,110 | -5,89 % | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD Confirms Immix, AWS, and Circadian Risk Participation at ISC West 2026 | Detroit, Michigan--(Newsfile Corp. - February 12, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the "Company"), a global leader in AI-driven security and productivity... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 46,080 | +0,96 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| LENZ THERAPEUTICS | 10,480 | -8,79 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign | Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The "Make it VIZZable" campaign features SJP enjoying... ► Artikel lesen | |
| KYVERNA THERAPEUTICS | 7,940 | -7,08 % | Kyverna Therapeutics: Ein kommender Biotech-Star? | Die Aktie von Kyverna Therapeutics rückt zunehmend in den Blick von Investoren, die auf bahnbrechende CAR-T-Therapien im Autoimmunbereich setzen. Mit vielversprechenden Studiendaten und einer bevorstehenden... ► Artikel lesen | |
| NUVALENT | 94,82 | -2,31 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen |
Das Unternehmen NANJING LEADS BIOLABS CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,44 % bei einem Aktienkurs von 6,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.